Myoview (Tetrofosmin)

Tetrofosmin is a lipophilic cation that is taken up by viable myocardial cells in proportion to regional blood flow. After intravenous injection, it accumulates in heart muscle, allowing single‑photon emission computed tomography (SPECT) to create detailed images of perfusion and identify areas of reduced blood supply.

The specific dose of Myoview is determined by the prescribing physician based on the patient’s clinical scenario, imaging protocol and regulatory guidelines. Healthcare professionals calculate the appropriate activity to achieve optimal image quality while adhering to radiation safety standards.

Myoview contains a radioactive tracer, so its use in pregnancy is generally avoided unless the diagnostic benefit outweighs potential fetal risk. Limited data exist for breastfeeding; if administered, breastfeeding may need to be paused according to local guidelines to minimize infant exposure.

To order Myoview, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details (including any cold‑chain requirements) and import documentation.

Myoview (tetrofosmin) is similar to other SPECT perfusion tracers such as thallium‑201 and technetium‑99m sestamibi. Compared with thallium‑201, tetrofosmin offers a lower radiation dose and longer half‑life, allowing flexible imaging times. Compared with sestamibi, it provides comparable image quality with a slightly different biodistribution, which may influence protocol selection.

Myoview should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. The vial should remain in its original packaging until use, and any unused portion should be disposed of according to local radiopharmaceutical waste regulations.

Myoview is administered as a sterile solution for intravenous injection. The prescribed activity is drawn into a syringe under aseptic conditions and injected into a peripheral vein, typically followed by a waiting period to allow tracer uptake before SPECT image acquisition.

Serious risks include rare anaphylactic reactions, severe hypotension, cardiac arrhythmias, and radiation‑related injury if exposure exceeds recommended limits. Patients should be monitored closely during and after administration, and any signs of allergic reaction or hemodynamic instability should be addressed immediately.

Myoview should be avoided in individuals with known hypersensitivity to tetrofosmin or any component of the formulation. It is also contraindicated in pregnant women unless essential, and caution is advised for patients with severe renal impairment, uncontrolled thyroid disorders, or those unable to tolerate intravenous injections.